Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,736 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Administration first Clear all

Conditions: Postural Orthostatic Tachycardia Syndrome
Interventions: Stimulation, Placebo; Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Glioblastoma
Interventions: Bevacizumab, Temozolomide, Radiation therapy, Placebo; Drug · Radiation
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 921 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 6 more

Conditions: Phantom Limb Pain
Interventions: Perineural infusion [continuous peripheral nerve block(s)]; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 4
States / cities: Palo Alto, California • San Diego, California • Bethesda, Maryland + 1 more

Conditions: Spinal Cord Injuries, Skeletal Muscle Atrophy, Metabolic Disease
Interventions: Neuromuscular electrical stimulation; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Lupus Nephritis
Interventions: zetomipzomib, placebo; Drug
Lead sponsor: Kezar Life Sciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Lake Charles, Louisiana • East Providence, Rhode Island • Colleyville, Texas + 1 more

Conditions: Cardiovascular Disease
Interventions: bococizumab (PF-04950615), Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 10,564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 518
States / cities: Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 328 more

Conditions: Major Depressive Disorder
Interventions: Low Dose Psilocybin, Placebo, Medium Dose Psilocybin; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: COVID-19, SARS-CoV-2
Interventions: AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 130 Years
Enrollment: 3,882 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 130
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more

Conditions: Anorexia, Cachexia, Fatigue, Lung Cancer
Interventions: infliximab, docetaxel, placebo; Biological · Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 188
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 116 more

Conditions: Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Interventions: Dasatinib + Quercetin, Placebo Capsules; Drug · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 60 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Borderline Personality Disorder
Interventions: Caplyta, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease
Interventions: LY2127399, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Irving, Texas

Conditions: Weight Gain
Interventions: Zonisamide, olanzapine, Sugar Pill (placebo); Drug
Lead sponsor: Lindner Center of HOPE; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Mason, Ohio

Conditions: Infertility, Female
Interventions: Follitropin delta, Placebo; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 35 Years to 42 Years · Female only
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 24
States / cities: Tempe, Arizona • Encino, California • Farmington, Connecticut + 21 more

Conditions: Oxidative Stress
Interventions: Placebo low dose, N Acetyl cysteine, 600mg (low dose), Proimmune 200 (FT061452) 3000mg low dose, Placebo (high dose), N Acetyl cysteine, 1200mg (high dose), FT061452, 6000mg high dose; Drug
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 30 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Andropause
Interventions: AndroGel® (testosterone gel), Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 65 Years and older · Male only
Enrollment: 790 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2018
U.S. locations: 12
States / cities: Birmingham, Alabama • La Jolla, California • Torrance, California + 9 more

Conditions: Urinary Retention, Urinary Tract Infections
Interventions: Tamsulosin, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Non Small Cell Lung Cancer (NSCLC)
Interventions: Dacomitinib, Doxycycline, Probiotic, Alclometasone cream; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 79
States / cities: Duarte, California • Fullerton, California • Irvine, California + 49 more

Conditions: Phenylketonuria
Interventions: Sapropterin dihydrochloride, Placebo; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 8 Years to 65 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 26
States / cities: La Jolla, California • Los Angeles, California • Palo Alto, California + 23 more

Conditions: Infertility
Interventions: Follitropin delta, Placebo; Drug · Other
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 579 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 23
States / cities: Tempe, Arizona • Encino, California • Farmington, Connecticut + 20 more

Conditions: Healthy
Interventions: BG00012 (dimethyl fumarate), BG00012 placebo, ASA, ASA placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 173 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Acute Kidney Injury
Interventions: RMC-035, Placebo; Drug
Lead sponsor: Guard Therapeutics AB; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 8
States / cities: Fort Wayne, Indiana • Lincoln, Nebraska • Rochester, New York + 5 more

Conditions: Dental Caries
Interventions: C16G2 Gel, Placebo; Drug · Other
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Imperial Beach, California • Indianapolis, Indiana • Boston, Massachusetts + 6 more

Conditions: Impotence, Prostatic Neoplasms
Interventions: Sildenafil therapy plus post-NSRRP HBO2T, Sildenafil therapy plus sham post-NSRRP HBO2T; Drug
Lead sponsor: Hartford Hospital; Other
Eligibility: 40 Years to 65 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 1
States / cities: Hartford, Connecticut

Search by objective public record fields.

Transdermal Vagal Stimulation for POTS

A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma

Treating Phantom Limb Pain Using Continuous Peripheral Nerve Blocks: A Department of Defense Funded Multicenter Study

Metabolic Health in Individuals With Spinal Cord Injury (SCI)

A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder

Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)

Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study

Caplyta in Borderline Personality Disorder

On Open-Label Study in Participants With Systemic Lupus Erythematosus

A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain

Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2)

The Effects of a Glutathione Precursor (FT061452),on Serum and Intracellular Glutathione Levels

The Testosterone Trials in Older Men

Prevention of Post-operative Urinary Retention

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients

Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1)

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery

Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects

Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer